FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2548417596> ?p ?o ?g. }

• W2548417596 endingPage "15951" @default.
• W2548417596 startingPage "15943" @default.
• W2548417596 abstract "We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. An open label, randomized, phase II trial was conducted at 6 centers; 160 patients were randomized (1:1) to either gefitinib alone or nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily) until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) at 3 months. Of the total 160 enrolled patients, 155 (77: gefitinib, 78: nimotuzumab plus gefitinib) received at least one dose and could be evaluated for efficacy and toxicity. The majority had adenocarcinoma (65.2%) and ECOG performance status of 0 to 1 (83.5%). The median follow-up was 22.1 months, and the PFS rate at 3 months was 48.1% in gefitinib and 37.2% in nimotuzumab plus gefitinib (P = not significant, NS). The median PFS and OS were 2.8 and 13.2 months in gefitinib and 2.0 and 14.0 months in nimotuzumab plus gefitinib. Combined treatment was not associated with superior PFS to gefitinib alone in patients with EGFR mutation (13.5 vs. 10.2 months in gefitinib alone, P=NS) or those with wild-type EGFR (0.9 vs. 2.0 months in gefitinib alone, P=NS). Combined treatment did not increase EGFR inhibition-related adverse events with manageable toxicities. The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefitinib alone as a second-line treatment of advanced NSCLC (NCT01498562)." @default.
• W2548417596 created "2016-11-11" @default.
• W2548417596 creator A5005358526 @default.
• W2548417596 creator A5005962138 @default.
• W2548417596 creator A5008594172 @default.
• W2548417596 creator A5016978421 @default.
• W2548417596 creator A5024070397 @default.
• W2548417596 creator A5047490140 @default.
• W2548417596 creator A5064697305 @default.
• W2548417596 creator A5065644915 @default.
• W2548417596 creator A5068310127 @default.
• W2548417596 creator A5073284312 @default.
• W2548417596 creator A5083550513 @default.
• W2548417596 date "2016-11-03" @default.
• W2548417596 modified "2023-10-16" @default.
• W2548417596 title "A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)" @default.
• W2548417596 cites W2056220279 @default.
• W2548417596 cites W2065141010 @default.
• W2548417596 cites W2073464554 @default.
• W2548417596 cites W2073541926 @default.
• W2548417596 cites W2083517004 @default.
• W2548417596 cites W2094417916 @default.
• W2548417596 cites W2108572537 @default.
• W2548417596 cites W2108572942 @default.
• W2548417596 cites W2114461323 @default.
• W2548417596 cites W2115131874 @default.
• W2548417596 cites W2129360604 @default.
• W2548417596 cites W2129432386 @default.
• W2548417596 cites W2129656399 @default.
• W2548417596 cites W2130357378 @default.
• W2548417596 cites W2133741785 @default.
• W2548417596 cites W2135293060 @default.
• W2548417596 cites W2137600224 @default.
• W2548417596 cites W2158180864 @default.
• W2548417596 cites W2165755768 @default.
• W2548417596 cites W2166084034 @default.
• W2548417596 cites W2167599107 @default.
• W2548417596 cites W2168340462 @default.
• W2548417596 cites W2234005477 @default.
• W2548417596 cites W2329444697 @default.
• W2548417596 doi "https://doi.org/10.18632/oncotarget.13056" @default.
• W2548417596 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5589698" @default.
• W2548417596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28903459" @default.
• W2548417596 hasPublicationYear "2016" @default.
• W2548417596 type Work @default.
• W2548417596 sameAs 2548417596 @default.
• W2548417596 citedByCount "10" @default.
• W2548417596 countsByYear W25484175962017 @default.
• W2548417596 countsByYear W25484175962019 @default.
• W2548417596 countsByYear W25484175962020 @default.
• W2548417596 countsByYear W25484175962021 @default.
• W2548417596 countsByYear W25484175962023 @default.
• W2548417596 crossrefType "journal-article" @default.
• W2548417596 hasAuthorship W2548417596A5005358526 @default.
• W2548417596 hasAuthorship W2548417596A5005962138 @default.
• W2548417596 hasAuthorship W2548417596A5008594172 @default.
• W2548417596 hasAuthorship W2548417596A5016978421 @default.
• W2548417596 hasAuthorship W2548417596A5024070397 @default.
• W2548417596 hasAuthorship W2548417596A5047490140 @default.
• W2548417596 hasAuthorship W2548417596A5064697305 @default.
• W2548417596 hasAuthorship W2548417596A5065644915 @default.
• W2548417596 hasAuthorship W2548417596A5068310127 @default.
• W2548417596 hasAuthorship W2548417596A5073284312 @default.
• W2548417596 hasAuthorship W2548417596A5083550513 @default.
• W2548417596 hasBestOaLocation W25484175961 @default.
• W2548417596 hasConcept C121608353 @default.
• W2548417596 hasConcept C126322002 @default.
• W2548417596 hasConcept C143998085 @default.
• W2548417596 hasConcept C203092338 @default.
• W2548417596 hasConcept C2776055544 @default.
• W2548417596 hasConcept C2776256026 @default.
• W2548417596 hasConcept C2776694085 @default.
• W2548417596 hasConcept C2779177807 @default.
• W2548417596 hasConcept C2779438470 @default.
• W2548417596 hasConcept C2780580887 @default.
• W2548417596 hasConcept C31760486 @default.
• W2548417596 hasConcept C535046627 @default.
• W2548417596 hasConcept C71924100 @default.
• W2548417596 hasConcept C81729549 @default.
• W2548417596 hasConcept C98274493 @default.
• W2548417596 hasConceptScore W2548417596C121608353 @default.
• W2548417596 hasConceptScore W2548417596C126322002 @default.
• W2548417596 hasConceptScore W2548417596C143998085 @default.
• W2548417596 hasConceptScore W2548417596C203092338 @default.
• W2548417596 hasConceptScore W2548417596C2776055544 @default.
• W2548417596 hasConceptScore W2548417596C2776256026 @default.
• W2548417596 hasConceptScore W2548417596C2776694085 @default.
• W2548417596 hasConceptScore W2548417596C2779177807 @default.
• W2548417596 hasConceptScore W2548417596C2779438470 @default.
• W2548417596 hasConceptScore W2548417596C2780580887 @default.
• W2548417596 hasConceptScore W2548417596C31760486 @default.
• W2548417596 hasConceptScore W2548417596C535046627 @default.
• W2548417596 hasConceptScore W2548417596C71924100 @default.
• W2548417596 hasConceptScore W2548417596C81729549 @default.
• W2548417596 hasConceptScore W2548417596C98274493 @default.
• W2548417596 hasIssue "9" @default.
• W2548417596 hasLocation W25484175961 @default.
• W2548417596 hasLocation W25484175962 @default.

• next